CoChat

Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A

Alexander, M S, Gasperini, M J, Tsai, P T, Gibbs, D E, Spinazzola, J M, Marshall, J L, Feyder, M J, Pletcher, M T, Chekler, E L P, Morris, C A, Sahin, M, Harms, J F, Schmidt, C J, Kleiman, R J, Kunkel, L M · 2016 · Translational Psychiatry
Cited by 19

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Duchenne muscular dystrophy is caused by mutations in the DYSTROPHIN gene. Although primarily associated with muscle wasting, a significant portion of patients (approximately 25%) are also diagnosed with autism spectrum disorder. We describe social behavioral deficits in dystrophin-deficient mice and present evidence of cerebellar deficits in cGMP production. We demonstrate therapeutic potential for selective inhibitors of the cGMP-specific PDE5A and PDE9A enzymes to restore social behaviors in dystrophin-deficient mice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/tp.2016.174

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 60

  1. Monaco AP, Neve RL, Colletti-Feener C, Bertelson CJ, Kurnit DM, Kunkel LM . Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 1986; 323: 646–650. · DOI · Paper page
  2. Hoffman EP, Brown RH, Kunkel LM . Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919–928. · DOI · Paper page
  3. Lidov HGW, Byers TJ, Watkins SC, Kunkel LM . Localization of dystrophin to postsynaptic regions of central nervous system cortical neurons. Nature 1990; 348: 725–728. · DOI · Paper page
  4. Lidov HGW, Byers TJ, Kunkel LM . The distribution of dystrophin in the murine central nervous system: an immunocytochemical study. Neuroscience 1993; 54: 167–187. · DOI · Paper page
  5. Pane M, Lombardo ME, Alfieri P, D'Amico A, Bianco F, Vasco G et al. Attention deficit hyperactivity disorder and cognitive function in Duchenne muscular dystrophy: phenotype-genotype correlation. J Pediatr 2012; 161: 705–9.e1. · DOI · Paper page
  6. Banihani R, Smile S, Yoon G, Dupuis A, Mosleh M, Snider A et al. Cognitive and neurobehavioral profile in boys with Duchenne muscular dystrophy. J Child Neurol 2015; 30: 1472–1482. · DOI · Paper page
  7. Ricotti V, Jagle H, Theodorou M, Moore AT, Muntoni F, Thompson DA . Ocular and neurodevelopmental features of Duchenne muscular dystrophy: a signature of dystrophin function in the central nervous system. Eur J Hum Genet 2015; 24: 562–568. · DOI
  8. Sigesmund DA, Weleber RG, Pillers D-AM, Westall CA, Panton CM, Powell BR et al. Characterization of the ocular phenotype of Duchenne and Becker muscular dystrophy. Ophthalmology 1994; 101: 856–865. · DOI
  9. Tremblay F, Laroche RG, De Becker I . The electroretinographic diagnosis of the incomplete form of congenital stationary night blindness. Vision Res 1995; 35: 2383–2393. · DOI
  10. Hinton VJ, Cyrulnik SE, Fee RJ, Batchelder A, Kiefel JM, Goldstein EM et al. Association of autistic spectrum disorders with dystrophinopathies. Pediatr Neurol 2009; 41: 339–346. · DOI
  11. Ricotti V, Mandy WPL, Scoto M, Pane M, Deconinck N, Messina S et al. Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. Dev Med Child Neurol 2015; 58: 77–84. · DOI · Paper page
  12. Hendriksen JGM, Vles JSH JSH . Neuropsychiatric disorders in males with Duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive-compulsive disorder. J Child Neurol 2008; 23: 477–481. · DOI · Paper page
  13. Duchenne de Boulogne GB . Recherches sur la paralysie musculaire pseudo-hypertrophiqueou paralysie myosclerosique. Arch Gen Med 1868; 11: 5–25.
  14. Leibowitz D, Dubowitz V . Intellect and behaviour in Duchenne muscular dystrophy. Dev Med Child Neurol 1981; 23: 577–590. · doi:10.1111/j.1469-8749.1981.tb02039.x
  15. Karagan NJ . Intellectual functioning in Duchenne muscular dystrophy: a review. Psychol Bull 1979; 86: 250–259. · doi:10.1037/0033-2909.86.2.250
  16. Kozicka A, Prot J, Wasilewski R . Mental retardation in patients with Duchenne progressive muscular dystrophy. J Neurol Sci 1971; 14: 209–213. · doi:10.1016/0022-510x(71)90090-6
  17. Hinton VJ, Nereo NE, Fee RJ, Cyrulnik SE . Social behavior problems in boys with Duchenne muscular dystrophy. J Dev Behav Pediatr 2006; 27: 470–476. · DOI · Paper page
  18. Cyrulnik SE, Fee RJ, De Vivo DC, Goldstein E, Hinton VJ . Delayed developmental language milestones in children with Duchenne's muscular dystrophy. J Pediatr 2007; 150: 474–478. · DOI
  19. Hinton VJ, De Vivo DC, Fee R, Goldstein E, Stern Y . Investigation of poor academic achievement in children with Duchenne muscular dystrophy. Learn Disabil Res Pract 2004; 19: 146–154. · DOI
  20. Hendriksen JGM, Vles JSH . Are males with Duchenne muscular dystrophy at risk for reading disabilities? Pediatr Neurol 2006; 34: 296–300. · DOI
  21. Hinton VJ, Fee RJ, Goldstein EM, De Vivo DC . Verbal and memory skills in males with Duchenne muscular dystrophy. Dev Med Child Neurol 2007; 49: 123–128. · DOI
  22. Carroll JE, Makari GS . Update on neuromuscular diseases of childhood. Curr Probl Pediatr 1989; 19: 118–166. · DOI
  23. Young HK, Barton BA, Waisbren S, Portales Dale L, Ryan MM, Webster RI et al. Cognitive and psychological profile of males with Becker muscular dystrophy. J Child Neurol 2008; 23: 155–162. · DOI
  24. Wingeier K, Giger E, Strozzi S, Kreis R, Joncourt F, Conrad B et al. Neuropsychological impairments and the impact of dystrophin mutations on general cognitive functioning of patients with Duchenne muscular dystrophy. J Clin Neurosci 2011; 18: 90–95. · DOI
  25. Krasowska E, Zabłocki K, Górecki DC, Swinny JD . Aberrant location of inhibitory synaptic marker proteins in the hippocampus of dystrophin-deficient mice: implications for cognitive impairment in Duchenne muscular dystrophy. PLoS One 2014; 9: e108364. · DOI
  26. Kim TW, Wu K, Black IB . Deficiency of brain synaptic dystrophin in human Duchenne muscular dystrophy. Ann Neurol 1995; 38: 446–449. · DOI
  27. Waite A, Tinsley CL, Locke M, Blake DJ . The neurobiology of the dystrophin-associated glycoprotein complex. Ann Med 2009; 41: 344–359. · DOI
  28. Kueh SL, Dempster J, Head SI, Morley JW . Reduced postsynaptic GABAA receptor number and enhanced gaboxadol induced change in holding currents in Purkinje cells of the dystrophin-deficient mdx mouse. Neurobiol Dis 2011; 43: 558–564. · DOI
  29. Chamova T, Guergueltcheva V, Raycheva M, Todorov T, Genova J, Bichev S et al. Association between loss of Dp140 and cognitive impairment in Duchenne and Becker dystrophies. Balkan J Med Genet 2013; 16: 21–30. · DOI · Paper page
  30. Bardoni A, Felisari G, Sironi M, Comi G, Lai M, Robotti M et al. Loss of Dp140 regulatory sequences is associated with cognitive impairment in dystrophinopathies. Neuromuscul Disord 2000; 10: 194–199. · DOI
  31. Connolly AM, Schierbecker J, Renna R, Florence J . High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002; 12: 917–925. · DOI
  32. Kawahara G, Karpf JA, Myers JA, Alexander MS, Guyon JR, Kunkel LM . Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2011; 108: 5331–5336. · DOI · Paper page
  33. Percival JM, Whitehead NP, Adams ME, Adamo CM, Beavo JA, Froehner SC . Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy. J Pathol 2012; 228: 77–87. · DOI
  34. De Arcangelis V, Strimpakos G, Gabanella F, Corbi N, Luvisetto S, Magrelli A et al. Pathways implicated in tadalafil amelioration of Duchenne muscular dystrophy. J Cell Physiol 2016; 231: 224–232. · DOI
  35. Nelson MD, Rader F, Tang X, Tavyev J, Nelson SF, Miceli MC et al. PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology 2014; 82: 2085–2091. · DOI
  36. Martin EA, Barresi R, Byrne BJ, Tsimerinov EI, Scott BL, Walker AE et al. Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci Transl Med 2012; 4: 162ra155. · DOI
  37. Rogers TD, McKimm E, Dickson PE, Goldowitz D, Blaha CD, Mittleman G . Is autism a disease of the cerebellum? An integration of clinical and pre-clinical research. Front Syst Neurosci 2013; 7: 15. · DOI · Paper page
  38. Shevelkin AV, Ihenatu C, Pletnikov MV . Pre-clinical models of neurodevelopmental disorders: focus on the cerebellum. Rev Neurosci 2014; 25: 177–194. · DOI
  39. Weber AM, Egelhoff JC, McKellop JM, Franz DN . Autism and the cerebellum: evidence from tuberous sclerosis. J Autism Dev Disord 2000; 30: 511–517. · DOI
  40. Hartell NA . Inhibition of cGMP breakdown promotes the induction of cerebellar long-term depression. J Neurosci 1996; 16: 2881–2890. · DOI
  41. Shimizu-Albergine M, Rybalkin SD, Rybalkina IG, Feil R, Wolfsgruber W, Hofmann F et al. Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): in vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. J Neurosci 2003; 23: 6452–6459. · DOI
  42. Claffey MM, Helal CJ, Verhoest PR, Kang Z, Fors KS, Jung S et al. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors. J Med Chem 2012; 55: 9055–9068. · doi:10.1021/jm3009635
  43. Adamo CM, Dai D-F, Percival JM, Minami E, Willis MS, Patrucco E et al. Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2010; 107: 19079–19083. · DOI · Paper page
  44. Silverman JL, Oliver CF, Karras MN, Gastrell PT, Crawley JN . AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology 2013; 64: 268–282. · DOI · Paper page
  45. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF et al. Preclinical characterization of selective phosphodiesterase 10 A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 2008; 325: 681–690. · DOI · Paper page
  46. Chapman VM, Miller DR, Armstrong D, Caskey CT . Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci USA 1989; 86: 1292–1296. · DOI · Paper page
  47. Snow WM, Fry M, Anderson JE . Increased density of dystrophin protein in the lateral versus the vermal mouse cerebellum. Cell Mol Neurobiol 2013; 33: 513–520. · DOI
  48. Anderson JL, Head SI, Morley JW . Long-term depression is reduced in cerebellar Purkinje cells of dystrophin-deficient mdx mice. Brain Res 2004; 1019: 289–292. · DOI
  49. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47–52.
  50. Pearson BL, Defensor EB, Blanchard DC, Blanchard RJ . C57BL/6 J mice fail to exhibit preference for social novelty in the three-chamber apparatus. Behav Brain Res 2010; 213: 189–194. · DOI · Paper page
  51. Leung DG, Herzka DA, Thompson WR, He B, Bibat G, Tennekoon G et al. Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. Ann Neurol 2014; 76: 541–549. · DOI
  52. Witting N, Kruuse C, Nyhuus B, Prahm KP, Citirak G, Lundgaard SJ et al. Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy. Ann Neurol 2014; 76: 550–557. · DOI
  53. Roseguini BT, Hirai DM, Alencar MC, Ramos RP, Silva BM, Wolosker N et al. Sildenafil improves skeletal muscle oxygenation during exercise in men with intermittent claudication. Am J Physiol Regul Integr Comp Physiol 2014; 307: R396–R404. · DOI
  54. Miranda R, Nagapin F, Bozon B, Laroche S, Aubin T, Vaillend C . Altered social behavior and ultrasonic communication in the dystrophin-deficient mdx mouse model of Duchenne muscular dystrophy. Mol Autism 2015; 6: 60. · DOI · Paper page
  55. Remmelink E, Aartsma-Rus A, Smit AB, Verhage M, Loos M, van Putten M . Cognitive flexibility deficits in a mouse model for the absence of full-length dystrophin. Genes Brain Behav 2016; 15: 558–567. · DOI · Paper page
  56. Kleiman RJ, Chapin DS, Christoffersen C, Freeman J, Fonseca KR, Geoghegan KF et al. Phosphodiesterase 9 A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J Pharmacol Exp Ther 2012; 341: 396–409. · DOI
  57. Hutson PH, Finger EN, Magliaro BC, Smith SM, Converso A, Sanderson PE et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3 S,4 S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 2011; 61: 665–676. · DOI
  58. Kroker KS, Rast G, Giovannini R, Marti A, Dorner-Ciossek C, Rosenbrock H . Inhibition of acetylcholinesterase and phosphodiesterase-9 A has differential effects on hippocampal early and late LTP. Neuropharmacology 2012; 62: 1964–1974. · DOI
  59. Kroker KS, Mathis C, Marti A, Cassel J-C, Rosenbrock H, Dorner-Ciossek C . PDE9 A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. Neurobiol Aging 2014; 35: 2072–2078. · DOI
  60. Vardigan JD, Converso A, Hutson PH, Uslaner JM . The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task. J Neurogenet 2011; 25: 120–126. · DOI

Cited by

See all 19

Metadata

Authors
Alexander, M. S., Gasperini, M. J., Tsai, P. T., Gibbs, D. E., Spinazzola, J. M., Marshall, J. L., Feyder, M. J., Pletcher, M. T., Chekler, E. L. P., Morris, C. A., Sahin, M., Harms, J. F., Schmidt, C. J., Kleiman, R. J., & Kunkel, L. M.
Venue
Translational Psychiatry
Published
2016-09-27
Volume
6
Issue
9
Pages
e901-e901
ISSN
2158-3188
Cited by
19
References
5
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A. https://app.cochat.ai/papers/10.1038/tp.2016.174
The paper
Alexander, M. S., Gasperini, M. J., Tsai, P. T., Gibbs, D. E., Spinazzola, J. M., Marshall, J. L., Feyder, M. J., Pletcher, M. T., Chekler, E. L. P., Morris, C. A., Sahin, M., Harms, J. F., Schmidt, C. J., Kleiman, R. J., & Kunkel, L. M. (2016). Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A. Translational Psychiatry. https://doi.org/10.1038/tp.2016.174

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.